Publication | Closed Access

A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results

Advanced Cervical CancerCervical CancerMedicinePharmacologyClinical TrialsGynecologyHydralazine ValproateEpigenetic TherapyPharmacotherapyAnti-cancer AgentCancer TreatmentOncologyGynecology Oncology